Role of fesoterodine in the treatment of overactive bladder

References

• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–766.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al; for Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2–6.
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6):1123–1128.
   PubMed Web of Science ®Google Scholar
• Brubaker L. Urgency: the cornerstone symptom of overactive bladder. Urology. 2004;64(6 Suppl 1):12–16.
   PubMedGoogle Scholar
• Abrams P Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
   PubMed Web of Science ®Google Scholar
• Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol. 2003;43(1):1–5.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80–S87.
   PubMedGoogle Scholar
• Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes – a possible sensory mechanism? J Physiol. 1997;505(2):503–511.
   PubMed Web of Science ®Google Scholar
• Downie JW, Dean DM. The contribution of cholinergic postganglionic neurotransmission to contractions of rabbit detrusor. J Pharmacol Exp Ther. 1977;203(2):417–425.
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279–290.
   PubMed Web of Science ®Google Scholar
• Eglen RM, Hegde S, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48(4):531–565.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Andersson KE, Mattiasson A. Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol. 1985;134(2):418–423.
   PubMed Web of Science ®Google Scholar
• Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273(2):959–966.
   PubMed Web of Science ®Google Scholar
• Goepel M, Gronewald A, Krege S, et al. Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urol Res. 1998;26(2):149–154.
   PubMedGoogle Scholar
• Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144(8):1089–1099.
   PubMed Web of Science ®Google Scholar
• Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Nat Acad Sci U S A. 2000;97(17):9579–9584.
   PubMed Web of Science ®Google Scholar
• Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. JAuton Pharmacol. 2001;21(5–6):243–248.
   Google Scholar
• Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641–643.
   PubMed Web of Science ®Google Scholar
• Matsui M, Motomura D, Fujikawa T, et al. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci. 2002;22(24):10627–10632.
   PubMed Web of Science ®Google Scholar
• Ehlert FJ. Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle. Life Sci. 2003;74(2–3):355–266.
   PubMed Web of Science ®Google Scholar
• Fredericks CM, Green RL, Anderson GF. Comparative in vitro effects of imipramine, oxybutynin, and flavoxate on rabbit detrusor. Urology. 1978;12(4):487–491.
   PubMedGoogle Scholar
• Paulson DF. Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. Urology. 1978;11(3):237–238.
   PubMedGoogle Scholar
• Moisey CU, StephensonTP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urology. 1980;52(6):472–475.
   PubMedGoogle Scholar
• Bary PR, Moisey CU, Stephenson TP, et al. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Prog Clin Biol Res. 1981;78:313–319.
   PubMedGoogle Scholar
• Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol. 1997;81(4):169–172.
   PubMedGoogle Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, et al; for Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414–421.
   PubMed Web of Science ®Google Scholar
• Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Cur Med Res Opin. 2002;18(4):177–184.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al; for the OPERA Study Group., Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–695.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68(2):328–332.
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 2007;51(4):1054–1064.
   PubMed Web of Science ®Google Scholar
• Andersson SH, Lindgren A, Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Met Disp. 1998;26(6):528–535.
   PubMed Web of Science ®Google Scholar
• Postlind HD, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Met Disp. 1998;26(4):289–293.
   PubMed Web of Science ®Google Scholar
• Palmér L, Andersson L, Andersson T, et al. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry. J Pharm Biomed Anal. 1997;16(1):155–165.
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJUInt. 2008;101(8):1036–1042.
   Google Scholar
• Khullar V Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839–843.
   PubMed Web of Science ®Google Scholar
• Michel MC, Hedge S. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol. 2006;374(2):79–85.
   PubMed Web of Science ®Google Scholar
• Brynne N, Dalén P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998;63(5):529–539.
   PubMed Web of Science ®Google Scholar
• Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol. 2001;41:851–850.
   PubMed Web of Science ®Google Scholar
• Simon HU, Malhotra B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Weekly. 2009;139(9–10):146–151.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Gandelman K, Sachse R, et al. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol. 2009;49(4):477–482.
   PubMed Web of Science ®Google Scholar
• Sachse R, Cawello W, Haag C, et al. Pharmacodynamics and pharmacokinetics of ascending multiple doses of the novel bladder-selective antimuscarinic fesoterodine. Eur Urol. 2003;2(1):30.
   Google Scholar
• Cawello W, Auer S, Hammes W, et al. Multiple dose pharmacokinetics of fesoterodine in human subjects. Naunyn-Schmiedebergs Arch Pharmacol. 2002;365(Suppl 1):R110.
   Google Scholar
• Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009;65(6):551–560.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46(11):556–563.
   Google Scholar
• Chapple C, V Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of Fesoterodine for overactive bladder syndromes. J Urol. 2007;178:2488–2494.
   PubMed Web of Science ®Google Scholar
• Sand PK, Morrow J, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynaecol J. 2009;20:827–835.
   PubMed Web of Science ®Google Scholar
• Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 1999;53(5):990–998.
   PubMed Web of Science ®Google Scholar
• Millard R, Tuttle J, Moore KH, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161(5):1551–1555.
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck PE, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn. 1998;17(5):499–512.
   PubMed Web of Science ®Google Scholar
• Hill S, Khullar V, Wyndaele JJ, et al; for the Darifenacin Study Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:239–247.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919–1924.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104(12):1374–1279.
   PubMedGoogle Scholar
• Chapple CR, Van Kerrebroeck P, Jünemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102(9):1128–1132.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102(1):56–61.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Pleil A, Reese PR, et al. How much is enough and who says so? BJOG. 2004;111(6):605–612.
   PubMed Web of Science ®Google Scholar
• Morris AR, Westbrook J, Moore KH. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity. BJOG. 2008;115(2):239–246.
   PubMed Web of Science ®Google Scholar
• Colli E, Digesu G, Olivieri L. Overactive bladder treatments in early phase clinical trials. Exp Opin Invest Drugs. 2007;16(7):999–1007.
   PubMed Web of Science ®Google Scholar
• Martos F, Bermudez R, Gomez A, et al. Characterization of muscarinic receptors in human submandibular salivary glands. Eur J Pharmacol. 1985;116(3):319–321.
   PubMed Web of Science ®Google Scholar
• Mansfield KJ, Mitchelson F, Moore KH, et al. Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes. Eur J Pharmacol. 2004;482(1–3):101–109.
   Web of Science ®Google Scholar
• Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560–567.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Fianu-Jonsson A, Indig M, et al; for the STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007;52(4):1195–1203.
   PubMed Web of Science ®Google Scholar
• Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23(4):248–252.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine – a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327(2–3):195–207.
   PubMed Web of Science ®Google Scholar
• Freeman R, Hill S, Millard R, et al; for the Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynaecol. 2003;102(3):605–611.
   Web of Science ®Google Scholar
• Chapple CR, Araño P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93(1):71–77.
   PubMed Web of Science ®Google Scholar
• Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin. 2006;22(1):41–48.
   PubMed Web of Science ®Google Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14–24.
   PubMedGoogle Scholar
• Zinner N, Gittelman M, Harris R, et al; for the Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 pt 1):2311–2315.
   PubMed Web of Science ®Google Scholar
• Finney SM, Andersson KE, Gillespie JI, et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503–507.
   PubMed Web of Science ®Google Scholar
• Hawthorn MH, Chapple CR, Cock M, et al. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129(3):416–419.
   PubMed Web of Science ®Google Scholar
• Bschleipfer T, Schukowski K, Weidner W, et al. Expression and distribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80(24–25):2303–2307.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Tyagi P, Van-le S, et al. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol. 2006;176(4 pt 1):1673–1678.
   PubMed Web of Science ®Google Scholar
• Mukerji G, YiangouY, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006;176(1):367–373.
   PubMed Web of Science ®Google Scholar
• Grol S, Essers P, van Koeveringe GA, et al. M(3) muscarinic receptor expression on suburothelial interstitial cells. BJU Int. 2009;104(3):398–405.
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65(2):238–242.
   PubMed Web of Science ®Google Scholar
• de Wachter S, Wyndaele JJ. Intravesical oxybutynin: A local anaesthetic effect on bladder C afferents. J Urol. 2003;169:1892–1895.
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Yusup A, Miwa Y, et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 2005;174(5):2032–2036.
   PubMed Web of Science ®Google Scholar
• Iijima K, de Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol. 2007;52(3):842–847.
   PubMed Web of Science ®Google Scholar
• de Laet K, de Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn. 2006;25(2):156–161.
   PubMed Web of Science ®Google Scholar
• Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia. 1991;29(2):84–90.
   PubMedGoogle Scholar
• Lose G, Norgaard JP. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int. 2001;87(9):767–773.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg s Arch Pharmacol. 2002;366(2):97–103.
   PubMed Web of Science ®Google Scholar
• Moriya H, Takagi Y, Nakanishi T, et al. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351–2358.
   PubMed Web of Science ®Google Scholar
• Watson N, Daniels DV, Ford AP, et al. Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells. Br J Pharmacol. 1999;127(2):590–596.
   PubMed Web of Science ®Google Scholar
• McNamara A, Pulido-Rios MT, Sweazey S, et al. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009;605(1–3):145–153.
   PubMed Web of Science ®Google Scholar
• Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007;30(1):54–58.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Sundquist S, Gillberg PG. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn. 1996;15:310–311.
   Google Scholar
• Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998;349(2–3):285–292.
   PubMed Web of Science ®Google Scholar
• Mansfield KJ, Chandran J, Vaux KJ, et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009;328(3):893–899.
   PubMed Web of Science ®Google Scholar
• Ito Y, Oyunzul L, Yoshida A, et al. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009;615(1–3):201–206.
   PubMed Web of Science ®Google Scholar